Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD134 Purified

Anti-Hu CD134 Purified

Anti-Hu CD134 Purified
Regulatory status
RUO
Antigen
CD134
Clone
Ber-ACT35
Format
Purified
Reactivity
Non-human primates, Human
Application
ELISA, IP, WB, FC (QC tested), IHC(F), IHC(P)
Variant
0.1 mg
11-152-C100
In stock
0.025 mg
11-152-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock
0.1 mg
11-261-C100
In stock
Contact us
Product details
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody Ber-ACT35 (also known as ACT35) recognizes an extracellular epitope of CD134 (TNFRSF4, OX40), an approximately 50 kDa type I transmembrane glycoprotein expressed on activated T cells.
Workshop
HLDA VI: WS Code C-31
Application
ELISA, IP, WB, FC (QC tested), IHC(F), IHC(P)
Reactivity
Non-human primates, Human
Immunogen
HTLV 1-transformed HUT-102 cells
Other names
TNFRSF4, OX40, ACT35, IMD16, TXGP1L
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, Karges W, Schlosser M, Eiermann T, Schendel DJ, Boehm BO: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2006 Jan;55(1):50-60.
PubMed
Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug;11(8):1426-38.
PubMed
Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15;93(10):3487-93.
PubMed
Li M, Zhang Y: The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol. 2005 Dec;2(6):467-71.
PubMed
Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol. 2007 Sep;82(3):576-84.
PubMed
Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 2006 Apr;80(7):3386-94.
PubMed
Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013 Oct 1;191(7):3641-50.
PubMed
Variant
0.1 mg
11-152-C100
In stock
0.025 mg
11-152-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock
0.1 mg
11-261-C100
In stock
Contact us
Datasheet download
SDS download
Bulk requests
Technical support for this product